Jeehoon Ghil
Incheon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 03, 2022
Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Journal: Journal of drugs in dermatology : JDD
Published: June 19, 2020
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Journal: Scandinavian journal of rheumatology
Published: May 30, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: January 07, 2020
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.
Journal: RMD open
Published: September 04, 2019
SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.
Journal: Therapeutic advances in gastroenterology
Published: August 09, 2019
Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
Journal: Current medical research and opinion
Published: December 19, 2018
Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.
Journal: The British journal of dermatology
Published: October 13, 2017
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 10, 2017
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 04, 2017
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.
Journal: Annals of the rheumatic diseases
Published: April 03, 2017
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
Journal: Rheumatology (Oxford, England)
Published: August 25, 2016
Last Updated: 09/26/2026